Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00086827 · ClinicalTrials.gov registry record · Phase 2

Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer

A Phase 2 study of Recurrent Small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
36
Enrollment target
1
Study location

NCT00086827 is a Phase 2 study of Recurrent Small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 52-participant average among 5 other Recurrent Small Cell Lung Cancer trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00086827, a Phase 2 study of Recurrent Small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

This phase II trial is studying how well FR901228 works in treating patients with recurrent small cell lung cancer. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

Conditions Studied

Recurrent Small Cell Lung Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG romidepsin

Study Locations (1)

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2004-05
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00086827

The ClinicalTrials.gov registry entry for NCT00086827 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52-participant average among 5 other Recurrent Small Cell Lung Cancer trials with a reported enrollment target (31% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.

NCT00086827 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00086827 about?

NCT00086827 is a clinical study titled "Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer". This phase II trial is studying how well FR901228 works in treating patients with recurrent small cell lung cancer. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

What is the current status of trial NCT00086827?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2004-05.

What conditions does trial NCT00086827 study?

This clinical trial studies the following conditions: Recurrent Small Cell Lung Cancer.

What interventions are being tested in trial NCT00086827?

The interventions under investigation include: laboratory biomarker analysis (OTHER), romidepsin (DRUG).

Who is sponsoring clinical trial NCT00086827?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00086827 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Small Cell Lung Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.